Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

X
Trial Profile

AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arsenic trioxide (Primary) ; Clofarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Laromustine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Everolimus; Fludarabine; Idarubicin; Lestaurtinib; Pacritinib; Temsirolimus; Tretinoin
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms AML-17; NCRI AML17
  • Most Recent Events

    • 12 Dec 2023 Results assessing comprehensive genotyping and molecular MRD assessment in two consecutive prospective randomised studies (NCRI AML17 (2009-2014) and AML19 (2015-2020)) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 10 Dec 2023 According to an American Society of Hematology media release, data from this study are being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight, by Jad Othman.
    • 10 Dec 2023 Results presented in an American Society of Hematology media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top